The US import of penicillins or streptomycins in dosage forms is projected to grow steadily from $697.22 million in 2024 to $759.54 million in 2028. In 2023, the actual value was $682.18 million, which suggests a positive trend with a forecasted annual growth rate of 2.1%. Observing year-on-year, there's a consistent approximate increase of 2.3% from 2024 onwards. The CAGR over the next five years is expected to be 2.2%, reflecting a stable increase in import value.

Future Trends to Watch For:

Monitored shifts in global antibiotic manufacturing and export markets, impacting costs and supply chains.
Regulatory changes or policy shifts regarding antibiotic imports and healthcare practices in the US.
Research on alternative antibiotic solutions potentially affecting traditional antibiotic demand.